Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Gaynor, ER; Unger, JM; Miller, TP; Grogan, TM; White, LA; Mills, GM; Balcerzak, SP; Varterasian, M; LeBlanc, M; Fisher, RI
   Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study
   JOURNAL OF CLINICAL ONCOLOGY
   
   E.R. Gaynor et al., "Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study", J CL ONCOL, 19(3), 2001, pp. 750-755
2. Oldham, RK; Reid, WK; Barnett, D
   Phase I study of CBT-1 (TM) and Taxol((R)) in patients with Taxol((R)) resistant cancers
   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
   
   R.K. Oldham et al., "Phase I study of CBT-1 (TM) and Taxol((R)) in patients with Taxol((R)) resistant cancers", CANC BIO R, 15(2), 2000, pp. 153-159
3. Belpomme, D; Gauthier, S; Pujade-Lauraine, E; Facchini, T; Goudier, MJ; Krakowski, I; Netter-Pinon, G; Frenay, M; Gousset, C; Marie, FN; Benmiloud, M; Sturtz, F
   Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma
   ANNALS OF ONCOLOGY
   
   D. Belpomme et al., "Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma", ANN ONCOL, 11(11), 2000, pp. 1471-1476
4. VANDEVRIE W; MARQUET RL; STOTER G; DEBRUIJN EA; EGGERMONT AMM
   IN-VIVO MODEL SYSTEMS IN P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE
   Critical reviews in clinical laboratory sciences
   
   W. Vandevrie et al., "IN-VIVO MODEL SYSTEMS IN P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE", Critical reviews in clinical laboratory sciences, 35(1), 1998, pp. 1-57
5. FERRY DR
   TESTING THE ROLE OF P-GLYCOPROTEIN EXPRESSION IN CLINICAL-TRIALS - APPLYING PHARMACOLOGICAL PRINCIPLES AND BEST METHODS FOR DETECTION TOGETHER WITH GOOD CLINICAL-TRIALS METHODOLOGY
   International journal of clinical pharmacology and therapeutics
   
   D.R. Ferry, "TESTING THE ROLE OF P-GLYCOPROTEIN EXPRESSION IN CLINICAL-TRIALS - APPLYING PHARMACOLOGICAL PRINCIPLES AND BEST METHODS FOR DETECTION TOGETHER WITH GOOD CLINICAL-TRIALS METHODOLOGY", International journal of clinical pharmacology and therapeutics, 36(1), 1998, pp. 29-40
6. LEHNERT M; MROSS K; SCHUELLER J; THUERLIMANN B; KROEGER N; KUPPER H
   PHASE-II TRIAL OF DEXVERAPAMIL AND EPIRUBICIN IN PATIENTS WITH NONRESPONSIVE METASTATIC BREAST-CANCER
   British Journal of Cancer
   
   M. Lehnert et al., "PHASE-II TRIAL OF DEXVERAPAMIL AND EPIRUBICIN IN PATIENTS WITH NONRESPONSIVE METASTATIC BREAST-CANCER", British Journal of Cancer, 77(7), 1998, pp. 1155-1163
7. PINKERTON CR
   MULTIDRUG-RESISTANCE IN CHILDHOOD SOLID TUMORS
   International journal of pediatric hematology/oncology
   
   C.R. Pinkerton, "MULTIDRUG-RESISTANCE IN CHILDHOOD SOLID TUMORS", International journal of pediatric hematology/oncology, 4(6), 1997, pp. 629-637
8. LEHNERT M; DEGIULI R; TWENTYMAN PR
   SENSITIVE AND RAPID BIOASSAY FOR ANALYSIS OF P-GLYCOPROTEIN-INHIBITING ACTIVITY OF CHEMOSENSITIZERS IN PATIENT
   Clinical cancer research
   
   M. Lehnert et al., "SENSITIVE AND RAPID BIOASSAY FOR ANALYSIS OF P-GLYCOPROTEIN-INHIBITING ACTIVITY OF CHEMOSENSITIZERS IN PATIENT", Clinical cancer research, 2(2), 1996, pp. 403-410
9. FERRY DR; TRAUNECKER H; KERR DJ
   CLINICAL-TRIALS OF P-GLYCOPROTEIN REVERSAL IN SOLID TUMORS
   European journal of cancer
   
   D.R. Ferry et al., "CLINICAL-TRIALS OF P-GLYCOPROTEIN REVERSAL IN SOLID TUMORS", European journal of cancer, 32A(6), 1996, pp. 1070-1081
10. LEHNERT M; DEGIULI R; KUNKE K; EMERSON S; DALTON WS; SALMON SE
    SERUM CAN INHIBIT REVERSAL OF MULTIDRUG-RESISTANCE BY CHEMOSENSITIZERS
    European journal of cancer
    
    M. Lehnert et al., "SERUM CAN INHIBIT REVERSAL OF MULTIDRUG-RESISTANCE BY CHEMOSENSITIZERS", European journal of cancer, 32A(5), 1996, pp. 862-867
11. CHEN G; TEICHER BA; FREI E
    DIFFERENTIAL INTERACTIONS OF PGP INHIBITOR THALIBLASTINE WITH ADRIAMYCIN, ETOPOSIDE, TAXOL AND ANTHRAPYRAZOLE CI941 IN SENSITIVE AND MULTIDRUG-RESISTANT HUMAN MCF-7 BREAST-CANCER CELLS
    Anticancer research
    
    G. Chen et al., "DIFFERENTIAL INTERACTIONS OF PGP INHIBITOR THALIBLASTINE WITH ADRIAMYCIN, ETOPOSIDE, TAXOL AND ANTHRAPYRAZOLE CI941 IN SENSITIVE AND MULTIDRUG-RESISTANT HUMAN MCF-7 BREAST-CANCER CELLS", Anticancer research, 16(6B), 1996, pp. 3499-3505
12. LIU Z; LHEUREUX F; POULIOT JF; HECKEL A; BAMBERGER U; GEORGES E
    BIBW22 BS, POTENT MULTIDRUG RESISTANCE-REVERSING AGENT, BINDS DIRECTLY TO P-GLYCOPROTEIN AND ACCUMULATES IN DRUG-RESISTANT CELLS
    Molecular pharmacology
    
    Z. Liu et al., "BIBW22 BS, POTENT MULTIDRUG RESISTANCE-REVERSING AGENT, BINDS DIRECTLY TO P-GLYCOPROTEIN AND ACCUMULATES IN DRUG-RESISTANT CELLS", Molecular pharmacology, 50(3), 1996, pp. 482-492
13. TAKESHITA H; GEBHARDT MC; SPRINGFIELD DS; KUSUZAKI K; MANKIN HJ
    EXPERIMENTAL-MODELS FOR THE STUDY OF DRUG-RESISTANCE IN OSTEOSARCOMA - P-GLYCOPROTEIN-POSITIVE, MURINE OSTEOSARCOMA CELL-LINES
    Journal of bone and joint surgery. American volume
    
    H. Takeshita et al., "EXPERIMENTAL-MODELS FOR THE STUDY OF DRUG-RESISTANCE IN OSTEOSARCOMA - P-GLYCOPROTEIN-POSITIVE, MURINE OSTEOSARCOMA CELL-LINES", Journal of bone and joint surgery. American volume, 78A(3), 1996, pp. 366-375
14. DEMMER A; DUNN T; HOOF T; KUBESCH P; TUMMLER B
    COMPETITIVE-INHIBITION OF PHOTOAFFINITY-LABELING OF P-GLYCOPROTEIN BYANTICANCER DRUGS AND MODULATORS INCLUDING S9788
    European journal of pharmacology
    
    A. Demmer et al., "COMPETITIVE-INHIBITION OF PHOTOAFFINITY-LABELING OF P-GLYCOPROTEIN BYANTICANCER DRUGS AND MODULATORS INCLUDING S9788", European journal of pharmacology, 315(3), 1996, pp. 339-343
15. BELLAMY WT; ODELEYE A; HUIZENGA E; DALTON WS; WEINSTEIN RS; GROGAN TM
    SEVERE COMBINED IMMUNODEFICIENCY (SCID) MOUSE MODELING OF P-GLYCOPROTEIN CHEMOSENSITIZATION IN MULTIDRUG-RESISTANT HUMAN MYELOMA XENOGRAFTS
    Clinical cancer research
    
    W.T. Bellamy et al., "SEVERE COMBINED IMMUNODEFICIENCY (SCID) MOUSE MODELING OF P-GLYCOPROTEIN CHEMOSENSITIZATION IN MULTIDRUG-RESISTANT HUMAN MYELOMA XENOGRAFTS", Clinical cancer research, 1(12), 1995, pp. 1563-1570
16. SONNEVELD P
    MODULATION OF MULTIDRUG-RESISTANCE IN MULTIPLE-MYELOMA
    Bailliere's clinical haematology
    
    P. Sonneveld, "MODULATION OF MULTIDRUG-RESISTANCE IN MULTIPLE-MYELOMA", Bailliere's clinical haematology, 8(4), 1995, pp. 831-844
17. MOORE AS; LEVEILLE CR; REIMANN KA; SHU H; ARIAS IM
    THE EXPRESSION OF P-GLYCOPROTEIN IN CANINE LYMPHOMA AND ITS ASSOCIATION WITH MULTIDRUG-RESISTANCE
    Cancer investigation
    
    A.S. Moore et al., "THE EXPRESSION OF P-GLYCOPROTEIN IN CANINE LYMPHOMA AND ITS ASSOCIATION WITH MULTIDRUG-RESISTANCE", Cancer investigation, 13(5), 1995, pp. 475-479
18. COWIE FJ; PINKERTON CR; PHILLIPS M; DICK G; JUDSON I; MCCARTHY PT; FLANAGAN RJ
    CONTINUOUS-INFUSION VERAPAMIL WITH ETOPOSIDE IN RELAPSED OR RESISTANTPEDIATRIC CANCERS
    British Journal of Cancer
    
    F.J. Cowie et al., "CONTINUOUS-INFUSION VERAPAMIL WITH ETOPOSIDE IN RELAPSED OR RESISTANTPEDIATRIC CANCERS", British Journal of Cancer, 71(4), 1995, pp. 877-881
19. LEHNERT M
    REVERSAL OF P-GLYCOPROTEIN-ASSOCIATED MULTIDRUG-RESISTANCE - FROM BENCH TO BEDSIDE
    Onkologie
    
    M. Lehnert, "REVERSAL OF P-GLYCOPROTEIN-ASSOCIATED MULTIDRUG-RESISTANCE - FROM BENCH TO BEDSIDE", Onkologie, 17(1), 1994, pp. 8-15
20. HILL BT; HOSKING LK
    DIFFERENTIAL EFFECTIVENESS OF A RANGE OF NOVEL DRUG-RESISTANCE MODULATORS, RELATIVE TO VERAPAMIL, IN INFLUENCING VINBLASTINE OR TENIPOSIDE CYTOTOXICITY IN HUMAN LYMPHOBLASTOID CCRF-CEM SUBLINES EXPRESSING CLASSIC OR ATYPICAL MULTIDRUG-RESISTANCE
    Cancer chemotherapy and pharmacology
    
    B.T. Hill e L.K. Hosking, "DIFFERENTIAL EFFECTIVENESS OF A RANGE OF NOVEL DRUG-RESISTANCE MODULATORS, RELATIVE TO VERAPAMIL, IN INFLUENCING VINBLASTINE OR TENIPOSIDE CYTOTOXICITY IN HUMAN LYMPHOBLASTOID CCRF-CEM SUBLINES EXPRESSING CLASSIC OR ATYPICAL MULTIDRUG-RESISTANCE", Cancer chemotherapy and pharmacology, 33(4), 1994, pp. 317-324
21. CROSTA L; CANDILORO V; MELI M; TOLOMEO M; RAUSA L; DUSONCHET L
    LACIDIPINE AND JOSAMYCIN - 2 NEW MULTIDRUG-RESISTANCE MODULATORS
    Anticancer research
    
    L. Crosta et al., "LACIDIPINE AND JOSAMYCIN - 2 NEW MULTIDRUG-RESISTANCE MODULATORS", Anticancer research, 14(6B), 1994, pp. 2685-2689
22. FRIDBORG H; LARSSON R; JUHLIN C; RASTAD J; AKERSTROM G; BACKLIN K; NYGREN P
    P-GLYCOPROTEIN EXPRESSION AND ACTIVITY OF RESISTANCE MODIFYING AGENTSIN PRIMARY CULTURES OF HUMAN RENAL AND ADRENOCORTICAL CARCINOMA-CELLS
    Anticancer research
    
    H. Fridborg et al., "P-GLYCOPROTEIN EXPRESSION AND ACTIVITY OF RESISTANCE MODIFYING AGENTSIN PRIMARY CULTURES OF HUMAN RENAL AND ADRENOCORTICAL CARCINOMA-CELLS", Anticancer research, 14(3A), 1994, pp. 1009-1016
23. POMMERENKE E; MATTERN J; VOLM M
    MODULATION OF DOXORUBICIN-TOXICITY BY TAMOXIFEN IN MULTIDRUG-RESISTANT TUMOR-CELLS IN-VITRO AND IN-VIVO
    Journal of cancer research and clinical oncology
    
    E. Pommerenke et al., "MODULATION OF DOXORUBICIN-TOXICITY BY TAMOXIFEN IN MULTIDRUG-RESISTANT TUMOR-CELLS IN-VITRO AND IN-VIVO", Journal of cancer research and clinical oncology, 120(7), 1994, pp. 422-426
24. RAMIREZ LH; MUNCK JN; ZHAO ZX; BOGNEL C; RICARD M; ARDOUIN P; ROUGIER P; GOUYETTE A
    VERAPAMIL-REVERSING CONCENTRATIONS INDUCE BLOOD-FLOW CHANGES THAT COULD COUNTERACT IN-VIVO THE MDR-1-MODULATING EFFECTS
    Cancer
    
    L.H. Ramirez et al., "VERAPAMIL-REVERSING CONCENTRATIONS INDUCE BLOOD-FLOW CHANGES THAT COULD COUNTERACT IN-VIVO THE MDR-1-MODULATING EFFECTS", Cancer, 74(3), 1994, pp. 810-816
25. FRIDBORG H; JONSSON B; NYGREN P; CSOKA K; NILSSON K; OBERG G; KRISTENSEN J; BERGH J; THOLANDER B; OLSEN L; JAKOBSON A; LARSSON R
    ACTIVITY OF CYCLOSPORINES AS RESISTANCE MODIFIERS IN PRIMARY CULTURESOF HUMAN HEMATOLOGICAL AND SOLID TUMORS
    British Journal of Cancer
    
    H. Fridborg et al., "ACTIVITY OF CYCLOSPORINES AS RESISTANCE MODIFIERS IN PRIMARY CULTURESOF HUMAN HEMATOLOGICAL AND SOLID TUMORS", British Journal of Cancer, 70(1), 1994, pp. 11-17
26. LIST AF; SPIER C; GREER J; WOLFF S; HUTTER J; DORR R; SALMON S; FUTSCHER B; BAIER M; DALTON W
    PHASE-I II TRIAL OF CYCLOSPORINE AS A CHEMOTHERAPY-RESISTANCE MODIFIER IN ACUTE-LEUKEMIA/
    Journal of clinical oncology
    
    A.F. List et al., "PHASE-I II TRIAL OF CYCLOSPORINE AS A CHEMOTHERAPY-RESISTANCE MODIFIER IN ACUTE-LEUKEMIA/", Journal of clinical oncology, 11(9), 1993, pp. 1652-1660
27. HILL BT; VANDERGRAAF WTA; HOSKING LK; DEVRIES EGE; MULDER NH; WHELAN RDH
    EVALUATION OF S9788 AS A POTENTIAL MODULATOR OF DRUG-RESISTANCE AGAINST HUMAN TUMOR SUBLINES EXPRESSING DIFFERING RESISTANCE MECHANISMS IN-VITRO
    International journal of cancer
    
    B.T. Hill et al., "EVALUATION OF S9788 AS A POTENTIAL MODULATOR OF DRUG-RESISTANCE AGAINST HUMAN TUMOR SUBLINES EXPRESSING DIFFERING RESISTANCE MECHANISMS IN-VITRO", International journal of cancer, 55(2), 1993, pp. 330-337
28. WIGLER PW; PATTERSON FK
    INHIBITION OF THE MULTIDRUG-RESISTANCE EFFLUX PUMP
    Biochimica et biophysica acta
    
    P.W. Wigler e F.K. Patterson, "INHIBITION OF THE MULTIDRUG-RESISTANCE EFFLUX PUMP", Biochimica et biophysica acta, 1154(2), 1993, pp. 173-181